Integration of Genomic Profiling and Organoid Development in Precision Oncology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Hyunho | - |
dc.contributor.author | Lee, Sanghoon | - |
dc.date.accessioned | 2022-05-17T12:41:38Z | - |
dc.date.available | 2022-05-17T12:41:38Z | - |
dc.date.created | 2022-05-17 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/141125 | - |
dc.description.abstract | Precision oncology involves an innovative personalized treatment strategy for each cancer patient that provides strategies and options for cancer treatment. Currently, personalized cancer medicine is primarily based on molecular matching. Next-generation sequencing and related technologies, such as single-cell whole-transcriptome sequencing, enable the accurate elucidation of the genetic landscape in individual cancer patients and consequently provide clinical benefits. Furthermore, advances in cancer organoid models that represent genetic variations and mutations in individual cancer patients have direct and important clinical implications in precision oncology. This review aimed to discuss recent advances, clinical potential, and limitations of genomic profiling and the use of organoids in breast and ovarian cancer. We also discuss the integration of genomic profiling and organoid models for applications in cancer precision medicine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject | GRADE SEROUS CARCINOMA | - |
dc.subject | BREAST-CANCER | - |
dc.subject | OVARIAN-CANCER | - |
dc.subject | PHASE-II | - |
dc.subject | DRIVER MUTATIONS | - |
dc.subject | HETEROGENEITY | - |
dc.subject | RESISTANCE | - |
dc.subject | TRASTUZUMAB | - |
dc.subject | PACLITAXEL | - |
dc.title | Integration of Genomic Profiling and Organoid Development in Precision Oncology | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sanghoon | - |
dc.identifier.doi | 10.3390/ijms23010216 | - |
dc.identifier.scopusid | 2-s2.0-85121668091 | - |
dc.identifier.wosid | 000759127900001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, no.1 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.volume | 23 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject.keywordPlus | GRADE SEROUS CARCINOMA | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | OVARIAN-CANCER | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | DRIVER MUTATIONS | - |
dc.subject.keywordPlus | HETEROGENEITY | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordAuthor | precision oncology | - |
dc.subject.keywordAuthor | next-generation sequencing | - |
dc.subject.keywordAuthor | organoids | - |
dc.subject.keywordAuthor | genome profiling | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | ovarian cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.